Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why Shares of Bicycle Therapeutics Were Rising on Monday Motley Fool - Mon Sep 11, 2023

The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.

NVS : 98.35 (-0.10%)
BCYC : 14.69 (+1.03%)
Why Bicycle Therapeutics Stock Raced Ahead Today Motley Fool - Thu Jul 13, 2023

The company's latest attempt at capital raising seems to be having enviable success.

GS : 582.79 (+2.10%)
JEF : 78.59 (+1.37%)
BCYC : 14.69 (+1.03%)
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Business Wire - Thu May 4, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets Business Wire - Thu May 4, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting Business Wire - Fri Apr 14, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics Enhances Leadership Team with Key Appointments Business Wire - Mon Apr 3, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates Business Wire - Tue Mar 28, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics to Participate in Upcoming Investor Conferences Business Wire - Tue Feb 28, 2023

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Business Wire - Tue Feb 28, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported...

BCYC : 14.69 (+1.03%)
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009 Business Wire - Tue Feb 14, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.69 (+1.03%)

Barchart Exclusives

Ford Stock 2025 Price Prediction: Will F Continue Paying Fat Dividends? Barchart - Wed Dec 25, 6:30PM CST
Ford stock is set to close in the red in 2024. However, its juicy dividend payouts could continue into the new year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot